Tedizolid phosphate (Sivextro®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001231
Authors' recomendations: Tedizolid phosphate (Sivextro®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with acute bacterial and skin structure infections (ABSSSI) caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant [MRSA] isolates) as an alternative oxazolidinione antibacterial. Treatment should only be initiated on advice from local microbiologists or specialists in infectious diseases. Tedizolid phosphate (Sivextro®) is not recommended for use within NHS Wales outside of this subpopulation/circumstance.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Humans
  • Anti-Bacterial Agents
  • Methicillin Resistance
  • Methicillin-Resistant Staphylococcus aureus
  • Skin Diseases, Bacterial
  • Staphylococcal Infections
  • Adult
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.